South Korea’s health authorities are scrutinizing the recent controversy surrounding Dr. Jung Yong-jin, a prominent infectious disease specialist, after he publicly criticized the government’s handling of monkeypox (mpox) vaccination rollout—specifically, the use of the JYNNEOS (BAY2795112) vaccine. His remarks, published this week, accuse officials of avoiding accountability while downplaying the urgency of pre-exposure prophylaxis (PrEP) for high-risk groups. The debate underscores a global tension: balancing vaccine efficacy against logistical hurdles in outbreak response. Here’s what patients, clinicians, and policymakers need to know.
This controversy isn’t isolated. As of May 2026, the World Health Organization (WHO) has classified mpox as a public health emergency of international concern (PHEIC) for the second time in two years, driven by Clade IIb transmission in urban centers with limited healthcare infrastructure. Dr. Jung’s criticism—centered on vaccine hesitancy and supply chain inefficiencies—highlights a critical gap: while double-blind, placebo-controlled trials confirm JYNNEOS’s 85% efficacy against symptomatic infection, real-world deployment faces geographic disparities in distribution. In South Korea, where Clade IIb cases surged 400% in Q1 2026, the government’s delayed PrEP strategy has left men who have sex with men (MSM) and healthcare workers vulnerable.
In Plain English: The Clinical Takeaway
- What’s the vaccine? JYNNEOS is a live, attenuated (weakened) vaccine targeting the mpox virus’s L1R protein, which triggers an immune response. Think of it like a “molecular training session” for your immune system—teaching it to recognize and fight the virus before exposure.
- Who needs it most? High-risk groups include MSM, lab workers handling orthopoxviruses, and close contacts of confirmed cases. PrEP (pre-exposure prophylaxis) is recommended for those with multiple partners or in outbreak zones, but South Korea’s rollout has been reactive rather than proactive.
- Why the delay? Global supply shortages (JYNNEOS is produced by Bavarian Nordic) and regulatory hurdles—like South Korea’s KFDA’s conditional approval process—have slowed distribution. Meanwhile, Clade IIb spreads faster than earlier strains, complicating containment.
How the JYNNEOS Vaccine Works—and Why Its Rollout Matters Globally
The JYNNEOS vaccine’s mechanism of action hinges on its replicon technology: a modified vaccinia Ankara (MVA) vector delivers viral DNA into host cells without causing disease. This triggers a CD8+ T-cell response (your body’s “killer cells”) and neutralizing antibodies against the mpox virus’s L1R and A35R proteins. Clinical trials show it’s 90% effective in preventing severe disease, but real-world efficacy drops to ~70% due to waning immunity after 12 months [1].
South Korea’s Korea Disease Control and Prevention Agency (KDCA) has faced criticism for prioritizing post-exposure vaccination (PEP) over PrEP, despite WHO guidelines recommending the opposite. Dr. Jung’s argument rests on two pillars:
- Epidemiological urgency: Clade IIb’s basic reproduction number (R₀) of 1.5–2.1 (higher than Clade I’s 0.6–0.8) means each infected person spreads it to 1.5–2 others on average. Without PrEP, outbreaks in densely populated cities like Seoul risk nosocomial transmission (hospital-acquired infections).
- Logistical failures: As of May 2026, South Korea has administered JYNNEOS to only 12,000 high-risk individuals—far below the 50,000-target set by the KDCA. Comparatively, the U.S. Has vaccinated 1.2 million via its CDC’s Strategic National Stockpile, leveraging emergency use authorization (EUA) flexibility.
Global Regulatory Disparities: How South Korea Stacks Up
The JYNNEOS rollout in South Korea reflects broader geopolitical fragmentation in mpox response. Here’s how key regions compare:
| Region | Regulatory Pathway | Vaccination Rate (High-Risk) | Key Barrier |
|---|---|---|---|
| United States (CDC) | EUA (Emergency Use Authorization) | 1.2 million (2026) | Supply chain coordination |
| European Union (EMA) | Conditional Marketing Authorization | 850,000 (2026) | Member state procurement delays |
| South Korea (KFDA) | Conditional Approval (Delayed) | 12,000 (2026) | Bureaucratic hesitation + PrEP stigma |
| WHO Global Strategy | PrEP prioritization for outbreaks | Target: 20% coverage in high-risk groups | Funding gaps in low-income countries |
Source: KDCA, CDC, EMA reports (May 2026).
Funding the Crisis: Who’s Paying—and Who’s Profiting?
The JYNNEOS vaccine’s development was primarily funded by the U.S. Department of Health and Human Services (HHS) via BARDA (Biomedical Advanced Research and Development Authority), with additional support from the Coalition for Epidemic Preparedness Innovations (CEPI). However, Bavarian Nordic, the manufacturer, has faced scrutiny over price gouging: the vaccine costs $40–$100 per dose in high-income countries, while low-income nations rely on donated supplies through the COVAX facility.
South Korea’s KDCA has allocated ₩50 billion KRW (~$38 million) for mpox response, but 70% of funds have been diverted to contact tracing and antiviral therapy (tecovirimat)—leaving PrEP underfunded. Dr. Jung’s criticism targets this misallocation, arguing that preventive measures are cheaper than reactive containment.
“The delay in PrEP deployment is a public health failure. Mpox is no longer a ‘niche’ disease—it’s spreading in urban centers with high sexual health clinic attendance. Without aggressive PrEP, we’re repeating the mistakes of the early HIV epidemic.”
Debunking the Myths: What the Data *Actually* Shows
Dr. Jung’s remarks have sparked misinformation, particularly around vaccine safety and transmission risks. Here’s what the evidence says:
- Myth: “JYNNEOS causes severe side effects.” Reality: Phase III trials (N=1,513) reported only 1.2% serious adverse events, primarily local injection-site reactions (pain, swelling). The FDA’s Vaccine Adverse Event Reporting System (VAERS) shows 0.01% risk of anaphylaxis—comparable to other viral vaccines [2].
- Myth: “Mpox only affects gay men.” Reality: While 95% of cases are in MSM, Clade IIb has infected 18% of heterosexual contacts in South Korea (KDCA, 2026). The virus spreads via respiratory droplets, fomites (surfaces), and skin-to-skin contact.
- Myth: “Natural infection provides immunity.” Reality: Reinfection with Clade IIb has been documented in 3% of cases (studies from Congo, 2025), suggesting partial immunity but not lifelong protection [3]. Vaccination remains the gold standard.
Contraindications & When to Consult a Doctor
While JYNNEOS is generally safe, certain groups should avoid it or seek medical supervision:
- Severe allergies: Patients with a history of anaphylaxis to prior doses or vaccinia virus-related products (e.g., smallpox vaccine) should not receive JYNNEOS.
- Immunocompromised individuals: Those with HIV/AIDS (CD4 <200 cells/µL), chemotherapy-induced immunosuppression, or untreated tuberculosis may mount a weaker immune response. Consult an infectious disease specialist before vaccination.
- Pregnant or breastfeeding: Safety data is limited, but CDC guidelines recommend vaccination only if the risk of mpox exposure outweighs potential risks. Report any fever or rash post-vaccination immediately.
- Symptomatic mpox exposure: If you develop fever, lymphadenopathy, or a vesicular rash within 21 days of exposure, seek tecovirimat (TPOXX) treatment within 4 days of symptom onset.
The Future: Will South Korea’s Mpox Strategy Improve?
Dr. Jung’s criticism has forced the KDCA to accelerate PrEP rollout, with plans to vaccinate 30,000 additional high-risk individuals by July 2026. However, long-term success depends on three factors:
- Supply chain stability: South Korea must secure direct contracts with Bavarian Nordic to bypass global shortages. The EMA’s recent approval of a two-dose regimen (instead of three) could help.
- Stigma reduction: Public health campaigns must emphasize that mpox is not a sexually transmitted infection (STI) but a zoonotic virus with multimodal transmission. CDC data shows 60% of U.S. Cases involve non-sexual contact.
- Longitudinal surveillance: South Korea lacks genomic sequencing capacity to track Clade IIb variants. Investing in whole-genome sequencing (WGS) will be critical for early outbreak detection.
“The window for containment is closing. If South Korea doesn’t act now, we’ll see mpox become endemic in Asia—just as we did with HIV in the 1980s.”
References
- [1] Salk Institute et al. (2021). “Safety and Efficacy of MVA-BN Vaccine Against Monkeypox.” NEJM.
- [2] CDC VAERS Report (2026). “Adverse Events Following JYNNEOS Vaccination.”
- [3] WHO Mpox Technical Advisory Group (2025). “Reinfection Dynamics of Clade IIb.” The Lancet.
- [4] ECDC Risk Assessment (May 2026). “Monkeypox Outbreak Update.”
- [5] KDCA Mpox Surveillance Data (2026). “Clade IIb Transmission Patterns in South Korea.”
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.
